Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16451476 | 0.87 | DRD3 (0.47) | DRD3BRD4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL12609669 | 0.80 | DRD3 (0.44) | DRD3 | |
| SCHEMBL12609797 | 0.80 | DRD3 (0.44) | DRD3 | |
| SCHEMBL14151172 | 0.80 | DRD3 (0.44) | DRD3 | |
| SCHEMBL14684802 | 0.80 | DRD3 (0.44) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL2387059 | 0.78 | DRD3 (0.43) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10747371 | 0.78 | PDE10A (0.46) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13634423 | 0.77 | ALDH1A1 (0.43) | BRD4 | |
| SCHEMBL13163980 | 0.77 | DRD3 (0.46) | DRD3CHEK1 | |
| SCHEMBL2298311 | 0.76 | DRD3 (0.41) | DRD3BRD4CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181230-B2 | Morpholine compounds and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150045359-A1 | MORPHOLINE COMPOUNDS AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045359-A1 | MORPHOLINE COMPOUNDS AND USES THEREOF | TAAR1, TAAR5, AGTR1 | DRD3 2259/4885BRD4 1348/4885CYP2D6 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.